BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for Mark Patton�
6.87
+0.23 (3.46%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.55 - 6.96
52 week 5.89 - 18.48
Open 6.59
Vol / Avg. 928,083.00/1.36M
Mkt cap 360.41M
P/E     -
Div/yield     -
EPS -1.38
Shares 52.46M
Beta 2.65
Inst. own 84%
Nov 3, 2015
Q3 2015 BioDelivery Sciences International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 9, 2015
BioDelivery Sciences International Inc at Wells Fargo Healthcare Conference - 9:25AM EDT - Add to calendar
Sep 9, 2015
BioDelivery Sciences International Inc at FBR Healthcare Conference Add to calendar
Aug 10, 2015
Q2 2015 BioDelivery Sciences International Inc Earnings Release
Aug 10, 2015
Q2 2015 BioDelivery Sciences International Inc Earnings Call
Jul 17, 2015
BioDelivery Sciences International Inc Annual Shareholders Meeting (Estimated)
Jul 16, 2015
BioDelivery Sciences International Inc Annual Shareholders Meeting
Jul 8, 2015
BioDelivery Sciences International Inc at Cantor Fitzgerald Inaugural Healthcare Conference
Jun 9, 2015
BioDelivery Sciences International Inc at William Blair Annual Growth Stock Conference
Jun 2, 2015
BioDelivery Sciences International Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1108.54% -139.22%
Operating margin -1077.96% -99.48%
EBITD margin - -96.66%
Return on average assets -92.07% -85.17%
Return on average equity -181.81% -202.39%
Employees 29 -
CDP Score - -

Address

4131 Parklake Avenue, Suite 225
RALEIGH, NC 27612
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.

Officers and directors

Frank E. O'Donnell Jr. MD Executive Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Mark A. Sirgo Pharm.D President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Ernest R. De Paolantonio CPA Chief Financial Officer, Treasurer, Secretary
Age: 62
Bio & Compensation  - Reuters
Andrew L. Finn Pharm.D. Executive Vice President - Product Development
Age: 66
Bio & Compensation  - Reuters
Stephana E. Patton Ph.D., J.D. Vice President, General Counsel
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Charles J. Bramlage Independent Director
Age: 54
Bio & Compensation  - Reuters
Thomas W. D'Alonzo Independent Director
Age: 71
Bio & Compensation  - Reuters
Barry I. Feinberg M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Samuel P. Sears Jr. Independent Director
Age: 71
Bio & Compensation  - Reuters